Institut du Fer à Moulin, Université Pierre et Marie Curie, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche S-839, Paris, France (A.B., S.D., V.S., S.M.B., I.M., K.B., L.M.); and Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina (T.K.).
Mol Pharmacol. 2014 Jan;85(1):127-38. doi: 10.1124/mol.113.089086. Epub 2013 Oct 30.
The putative role of the N-terminal region of rhodopsin-like 7 transmembrane biogenic amine receptors in agonist-induced signaling has not yet been clarified despite recent advances in 7 transmembrane receptor structural biology. Given the existence of N-terminal nonsynonymous polymorphisms (R6G;E42G) within the HTR2B gene in a drug-abusing population, we assessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharmacologic and coupling properties in transfected COS-7 cells. Modification of the 5-HT2B receptor N terminus by the R6G;E42G polymorphisms increases such agonist signaling pathways as inositol phosphate accumulation as assessed by either classic or operational models. The N-terminal R6G;E42G mutations of the 5-HT2B receptor also increase cell proliferation and slow its desensitization kinetics compared with the wild-type receptor, further supporting a role for the N terminus in transduction efficacy. Furthermore, by coexpressing a tethered wild-type 5-HT2B receptor N terminus with a 5-HT2B receptor bearing a N-terminal deletion, we were able to restore original coupling. This reversion to normal activity of a truncated 5-HT2B receptor by coexpression of the membrane-tethered wild-type 5-HT2B receptor N terminus was not observed using a membrane-tethered 5-HT2B receptor R6G;E42G N terminus. These data suggest that the N terminus exerts a negative control over basal as well as agonist-stimulated receptor activity that is lost in the R6G;E42G mutant. Our findings reveal a new and unanticipated role of the 5-HT2B receptor N terminus as a negative modulator, affecting both constitutive and agonist-stimulated activity. Moreover, our data caution against excluding the N terminus and extracellular loops in structural studies of this 7 transmembrane receptor family.
尽管 7 跨膜受体结构生物学最近取得了进展,但 7 跨膜生物胺受体的假定作用,如 rhodopsin 样受体的 N 端区域在激动剂诱导的信号转导中的作用仍不清楚。由于在滥用药物人群的 HTR2B 基因中存在 N 端非同义多态性(R6G;E42G),我们评估了这些多态性是否会影响转染 COS-7 细胞中 5-羟色胺 2B(5-HT2B)受体的体外药理和偶联特性。通过经典或操作性模型评估,通过 5-HT2B 受体 N 端的 R6G;E42G 多态性修饰,增加了激动剂信号通路,如肌醇磷酸盐积累。与野生型受体相比,5-HT2B 受体的 N 端 R6G;E42G 突变还增加了细胞增殖并减缓其脱敏动力学,进一步支持 N 端在转导效率中的作用。此外,通过共表达具有 N 端缺失的 5-HT2B 受体与膜结合的野生型 5-HT2B 受体 N 端,我们能够恢复原始偶联。通过共表达膜结合的野生型 5-HT2B 受体 N 端,未观察到具有 N 端缺失的截断 5-HT2B 受体通过共表达恢复正常活性,而不是使用膜结合的 5-HT2B 受体 R6G;E42G N 端。这些数据表明,N 端对基础和激动剂刺激的受体活性施加负控制,而在 R6G;E42G 突变体中失去了这种控制。我们的发现揭示了 5-HT2B 受体 N 端作为负调节剂的新的和意外作用,影响组成型和激动剂刺激的活性。此外,我们的数据提醒人们在对该 7 跨膜受体家族进行结构研究时,不要排除 N 端和细胞外环。